Elena Alekseevna Sosnova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elena Alekseevna Sosnova has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Evgeniya Alexandrovna Svidinskaya
Sechenov First Moscow State Medical University (Sechenov University)
16 shared publications - Lidiya A. Klyukina
I.M. Sechenov First Moscow State Medical University
13 shared publications - Mikhail Borisovich Ageev
Sechenov First Moscow State Medical University (Sechenov University)
11 shared publications - Anton A. Ishchenko
Medical and Rehabilitation Center
7 shared publications Клюкина Лидия Александровна
Первый Московский государственный медицинский университет им. И.М. Сеченова; Центр иммунологии и репродукции
7 shared publications- Mikhail M. Davydov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
4 shared publications
Latest Publications
- Open Access
- 14 November 2026
- Published by ECO-Vector LLC (Publications) in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 13 (3) , 222-228
Features of anesthetic management and anesthetic risks in patients taking combined oral contraceptives and menopausal hormone therapy
This review is based on the analysis of domestic and foreign studies published in peer-reviewed medical journals, and clinical guidelines devoted to anesthetic management of patients receiving combined oral contraceptives and menopausal hormone therapy. For the search of publications, the PubMed database and specialized Russian journals were used. The review included studies published in 1990–2025, with emphasis on systematic reviews, randomized controlled trials, large cohort studies, and current clinical guidelines. Combined oral contraceptives and menopausal hormone therapy are widely used in gynecology; however, they increase the risk of venous thromboembolic complications, especially in the perioperative period. Anesthetic management requires careful assessment of thrombotic risk, consideration of interactions of hormonal drugs with anesthetics, sugammadex, and antibiotics, as well as an individualized approach to continuation or discontinuation of therapy. It is recommended to discontinue oral forms of combined oral contraceptives and menopausal hormone therapy 4–6 weeks before high-risk operations, to give preference to transdermal forms of menopausal hormone therapy, to conduct enhanced thromboprophylaxis with low-molecular-weight heparins, and to mandatory inform patients about the need for additional contraception after the use of sugammadex. Particular attention should be given to patients with thrombophilias and comorbidity. Systematization of data contributes to improving the safety of anesthetic management in this category of patients.
- 14 November 2026
- Published by ECO-Vector LLC (Publications) in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 13 (3) , 222-228
Open AccessFeatures of anesthetic management and anesthetic risks in patients taking combined oral contraceptives and menopausal hormone therapy
This review is based on the analysis of domestic and foreign studies published in peer-reviewed medical journals, and clinical guidelines devoted to anesthetic management of patients receiving combined oral contraceptives and menopausal hormone therapy. For the search of publications, the PubMed database and specialized Russian journals were used. The review included studies published in 1990–2025, with emphasis on systematic reviews, randomized controlled trials, large cohort studies, and current clinical guidelines. Combined oral contraceptives and menopausal hormone therapy are widely used in gynecology; however, they increase the risk of venous thromboembolic complications, especially in the perioperative period. Anesthetic management requires careful assessment of thrombotic risk, consideration of interactions of hormonal drugs with anesthetics, sugammadex, and antibiotics, as well as an individualized approach to continuation or discontinuation of therapy. It is recommended to discontinue oral forms of combined oral contraceptives and menopausal hormone therapy 4–6 weeks before high-risk operations, to give preference to transdermal forms of menopausal hormone therapy, to conduct enhanced thromboprophylaxis with low-molecular-weight heparins, and to mandatory inform patients about the need for additional contraception after the use of sugammadex. Particular attention should be given to patients with thrombophilias and comorbidity. Systematization of data contributes to improving the safety of anesthetic management in this category of patients.
- 20 May 2026
- Published by ECO-Vector LLC (Publications) in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 13 (2) , 140-149
THE RELEVANCE OF THE STUDY OF microRNA IN MODERN OBSTETRICS AND GYNECOLOGY
MicroRNAs (miRNAs) are one of the most actively studied classes of small non-coding RNAs in modern medicine. A review of current studies on this topic is presented both in Russian and in English. The key advantage of microRNAs as potential biomarkers is their high stability in biological fluids (blood, urine, amniotic fluid, cervical mucus), tissue specificity and the possibility of non-invasive determination. In recent years, various studies have been conducted to identify such a biomarker as microRNAs in the blood plasma of women diagnosed with endometriosis. Complex intracellular interactions between signaling pathways suggest that microRNAs may be related to the pathophysiology of endometriosis, as they regulate numerous processes, including apoptosis and cell proliferation. The analyzed studies demonstrate that changes in the expression of microRNAs are associated with a number of pregnancy complications, such as disorders of uteroplacental-fetal blood flow, preeclampsia. Modern data allow us to consider microRNA dysregulation as one of the central molecular mechanisms for the development of isthmic-cervical insufficiency, and the results of pilot studies confirm the prospects for the use of mRNA technologies for the pathogenetic correction of chronic placental insufficiency. Promising areas for future research are large-scale validation of miRNA biomarkers, the development of safe methods for their local modulation, and an in-depth study of the role of exosomes in the pathogenesis of many diseases.
- 20 May 2026
- Published by ECO-Vector LLC (Publications) in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 13 (2) , 140-149
THE RELEVANCE OF THE STUDY OF microRNA IN MODERN OBSTETRICS AND GYNECOLOGY
MicroRNAs (miRNAs) are one of the most actively studied classes of small non-coding RNAs in modern medicine. A review of current studies on this topic is presented both in Russian and in English. The key advantage of microRNAs as potential biomarkers is their high stability in biological fluids (blood, urine, amniotic fluid, cervical mucus), tissue specificity and the possibility of non-invasive determination. In recent years, various studies have been conducted to identify such a biomarker as microRNAs in the blood plasma of women diagnosed with endometriosis. Complex intracellular interactions between signaling pathways suggest that microRNAs may be related to the pathophysiology of endometriosis, as they regulate numerous processes, including apoptosis and cell proliferation. The analyzed studies demonstrate that changes in the expression of microRNAs are associated with a number of pregnancy complications, such as disorders of uteroplacental-fetal blood flow, preeclampsia. Modern data allow us to consider microRNA dysregulation as one of the central molecular mechanisms for the development of isthmic-cervical insufficiency, and the results of pilot studies confirm the prospects for the use of mRNA technologies for the pathogenetic correction of chronic placental insufficiency. Promising areas for future research are large-scale validation of miRNA biomarkers, the development of safe methods for their local modulation, and an in-depth study of the role of exosomes in the pathogenesis of many diseases.
- Open Access
- 25 March 2026
- Published by ECO-Vector LLC (Publications) in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 13 (1) , 5-12
Comparative analysis of syphilis incidence among pregnant women in Russia and China: epidemiology, control strategies, and prevention
Despite similarities in healthcare system organization, the incidence of congenital syphilis remains stable in Russia, whereas a marked decline has been achieved in China. The question remains which systemic factors constitute key barriers in Russia. This study seeks to identify and quantitatively assess specific gaps in screening, monitoring, and treatment of syphilis among pregnant women in Russia that hinder effective adoption of successful Chinese practices. The work aimed to perform a comparative analysis of syphilis incidence among pregnant women in Russia and China. A retrospective analysis was conducted using data from the Russian Federal State Statistics Service, the Chinese Center for Disease Control and Prevention, and scientific publications (2013–2023). In China, a decline in syphilis incidence among pregnant women has been observed due to mandatory trimester-based screening (coverage 99%) and a comprehensive program for the prevention of mother-to-child transmission. The incidence of congenital syphilis decreased from 91.6 to 18.4 cases per 100,000 live births (between 2011 and 2018). In Russia, the incidence remains consistently high (13.1–17.6 per 100,000 population in 2020–2023), with more than 30% of women entering antenatal care in the second or third trimester. Data on treatment coverage are lacking. Reducing the burden of congenital syphilis in Russia may be facilitated by standardization of screening protocols and implementation of monitoring systems ensuring early antenatal registration. The success of the Chinese model is driven by comprehensive screening and integration of services within the national healthcare system, which is comparable to that of the Russian Federation.
- 25 March 2026
- Published by ECO-Vector LLC (Publications) in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 13 (1) , 5-12
Open AccessComparative analysis of syphilis incidence among pregnant women in Russia and China: epidemiology, control strategies, and prevention
Despite similarities in healthcare system organization, the incidence of congenital syphilis remains stable in Russia, whereas a marked decline has been achieved in China. The question remains which systemic factors constitute key barriers in Russia. This study seeks to identify and quantitatively assess specific gaps in screening, monitoring, and treatment of syphilis among pregnant women in Russia that hinder effective adoption of successful Chinese practices. The work aimed to perform a comparative analysis of syphilis incidence among pregnant women in Russia and China. A retrospective analysis was conducted using data from the Russian Federal State Statistics Service, the Chinese Center for Disease Control and Prevention, and scientific publications (2013–2023). In China, a decline in syphilis incidence among pregnant women has been observed due to mandatory trimester-based screening (coverage 99%) and a comprehensive program for the prevention of mother-to-child transmission. The incidence of congenital syphilis decreased from 91.6 to 18.4 cases per 100,000 live births (between 2011 and 2018). In Russia, the incidence remains consistently high (13.1–17.6 per 100,000 population in 2020–2023), with more than 30% of women entering antenatal care in the second or third trimester. Data on treatment coverage are lacking. Reducing the burden of congenital syphilis in Russia may be facilitated by standardization of screening protocols and implementation of monitoring systems ensuring early antenatal registration. The success of the Chinese model is driven by comprehensive screening and integration of services within the national healthcare system, which is comparable to that of the Russian Federation.
- Open Access
- 17 March 2026
- Published by ECO-Vector LLC (Publications) in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 13 (1) , 13-24
Impact of the glucagon-like peptide-1 receptor agonist semaglutide on reproductive health of women with obesity: a review of clinical evidence
Currently, the problem of overweight and obesity has acquired global significance due to the high prevalence of these conditions and the associated multisystem pathological conditions, including reproductive disorders in both men and women. Contemporary medicine strongly recommends weight reduction to prevent metabolic complications and obesity-related comorbidities. The most effective and fundamental approach remains lifestyle modification, including a hypocaloric diet and moderate physical activity. However, a proportion of patients demonstrate resistance to such changes, necessitating the use of pharmacological agents and, in some cases, surgical treatment. Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated high efficacy in reducing body weight and improving glycemic control in patients with obesity and type 2 diabetes mellitus. However, data on the effects of semaglutide on the female reproductive system remain limited, as long-term clinical observations and studies under extreme conditions have been predominantly conducted in animal models. Particular attention is given to the effects of the drug in women of reproductive age, including its impact during preconception, the first trimester of pregnancy, and lactation, when both inadvertent and intentional exposure may have unpredictable consequences for the fetus and infant. This study presents a systematic review of current evidence regarding the use of semaglutide in female patients with obesity and examines the associated risks and contraindications during specific physiological states such as pregnancy and lactation. The findings are of substantial importance for developong clinical guidelines and establishing safe therapeutic strategies, which are essential for preserving reproductive health and supporting demographic stability.
- 17 March 2026
- Published by ECO-Vector LLC (Publications) in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 13 (1) , 13-24
Open AccessImpact of the glucagon-like peptide-1 receptor agonist semaglutide on reproductive health of women with obesity: a review of clinical evidence
Currently, the problem of overweight and obesity has acquired global significance due to the high prevalence of these conditions and the associated multisystem pathological conditions, including reproductive disorders in both men and women. Contemporary medicine strongly recommends weight reduction to prevent metabolic complications and obesity-related comorbidities. The most effective and fundamental approach remains lifestyle modification, including a hypocaloric diet and moderate physical activity. However, a proportion of patients demonstrate resistance to such changes, necessitating the use of pharmacological agents and, in some cases, surgical treatment. Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated high efficacy in reducing body weight and improving glycemic control in patients with obesity and type 2 diabetes mellitus. However, data on the effects of semaglutide on the female reproductive system remain limited, as long-term clinical observations and studies under extreme conditions have been predominantly conducted in animal models. Particular attention is given to the effects of the drug in women of reproductive age, including its impact during preconception, the first trimester of pregnancy, and lactation, when both inadvertent and intentional exposure may have unpredictable consequences for the fetus and infant. This study presents a systematic review of current evidence regarding the use of semaglutide in female patients with obesity and examines the associated risks and contraindications during specific physiological states such as pregnancy and lactation. The findings are of substantial importance for developong clinical guidelines and establishing safe therapeutic strategies, which are essential for preserving reproductive health and supporting demographic stability.
- Open Access
- 2 March 2026
- Published by ECO-Vector LLC (Publications) in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 13 (1) , 34-47
Management of pregnancy in patients with rheumatic diseases: modern therapeutic options
Rheumatic diseases such as systemic lupus erythematosus and rheumatoid arthritis frequently begin in reproductive age, resulting in a high incidence of autoimmune disorders during pregnancy. Managing these patients is challenging, necessitating a balance between effective control of rheumatic disease activity for a favorable pregnancy outcome and minimizing risks to the fetus. This paper summarizes modern approaches to preconception care, pregnancy management, safe therapy selection, and monitoring of complications in patients with rheumatic diseases, primarily systemic lupus erythematosus and rheumatoid arthritis. The paper reviews relevant guidelines, including the updated 2024 EULAR, data from national and international registries, and findings of cohort and retrospective studies on pregnancy outcomes in patients with rheumatic diseases. Rheumatic disease activity during conception and gestation is a key predictor of adverse outcomes such as pre-eclampsia, fetal growth retardation, preterm delivery, and congenital abnormalities. Achieving sustained remission 6–12 months before pregnancy considerably increases the likelihood of having a healthy child. The therapeutic strategy is based on the personalized selection of drugs that are suitable for pregnancy and lactation. Hydroxychloroquine is essential for the treatment of systemic lupus erythematosus owing to its immunomodulatory and antithrombotic properties, established safety profile, and positive impact on outcomes. Tumor necrosis factor inhibitors can be used in rheumatoid arthritis until late pregnancy or in patients with high disease activity. Methotrexate, mycophenolate mofetil, and cyclophosphamide are strictly contraindicated during pregnancy and must be discontinued at the planning stage. Effective disease control requires multidisciplinary collaboration between a rheumatologist and an obstetrician-gynecologist at all stages, from preconception counseling and follow-up during pregnancy to postpartum care. Thus, favorable pregnancy outcomes in patients with rheumatic diseases are possible with careful pregnancy planning when in remission, safe and effective maintenance therapy, and continuous multidisciplinary monitoring. Adherence to these principles reduces risks for both mother and fetus.
- 2 March 2026
- Published by ECO-Vector LLC (Publications) in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 13 (1) , 34-47
Open AccessManagement of pregnancy in patients with rheumatic diseases: modern therapeutic options
Rheumatic diseases such as systemic lupus erythematosus and rheumatoid arthritis frequently begin in reproductive age, resulting in a high incidence of autoimmune disorders during pregnancy. Managing these patients is challenging, necessitating a balance between effective control of rheumatic disease activity for a favorable pregnancy outcome and minimizing risks to the fetus. This paper summarizes modern approaches to preconception care, pregnancy management, safe therapy selection, and monitoring of complications in patients with rheumatic diseases, primarily systemic lupus erythematosus and rheumatoid arthritis. The paper reviews relevant guidelines, including the updated 2024 EULAR, data from national and international registries, and findings of cohort and retrospective studies on pregnancy outcomes in patients with rheumatic diseases. Rheumatic disease activity during conception and gestation is a key predictor of adverse outcomes such as pre-eclampsia, fetal growth retardation, preterm delivery, and congenital abnormalities. Achieving sustained remission 6–12 months before pregnancy considerably increases the likelihood of having a healthy child. The therapeutic strategy is based on the personalized selection of drugs that are suitable for pregnancy and lactation. Hydroxychloroquine is essential for the treatment of systemic lupus erythematosus owing to its immunomodulatory and antithrombotic properties, established safety profile, and positive impact on outcomes. Tumor necrosis factor inhibitors can be used in rheumatoid arthritis until late pregnancy or in patients with high disease activity. Methotrexate, mycophenolate mofetil, and cyclophosphamide are strictly contraindicated during pregnancy and must be discontinued at the planning stage. Effective disease control requires multidisciplinary collaboration between a rheumatologist and an obstetrician-gynecologist at all stages, from preconception counseling and follow-up during pregnancy to postpartum care. Thus, favorable pregnancy outcomes in patients with rheumatic diseases are possible with careful pregnancy planning when in remission, safe and effective maintenance therapy, and continuous multidisciplinary monitoring. Adherence to these principles reduces risks for both mother and fetus.
- 10 December 2025
- Published by ECO-Vector LLC (Publications) in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 12 (4) , 381-394
Correction of vitamin status in pregnant women: current approaches and clinical significance
This systematic review aims to summarize current evidence on vitamin deficiencies in pregnant women, their clinical consequences, and approaches to nutritional status correction during gestation. Given the increasing prevalence of hypovitaminosis among pregnant women, particularly deficiencies of folic acid, vitamin D, and vitamin B12, the clinical importance of early diagnosis and individualized therapy is growing. The article analyzes studies published over the past 5 years by Russian and international authors, including randomized controlled trials, meta-analyses, cohort studies, and international clinical guidelines. Key micronutrients, their effects on the course of pregnancy, maternal and fetal outcomes, and factors contributing to impaired vitamin metabolism, including genetic polymorphisms (MTHFR, VDR, TCN2), were evaluated. The review presents approaches to laboratory diagnosis of vitamin deficiencies, principles of rational dietary therapy, and the use of vitamin–mineral supplements, as well as the potential of personalized nutritional correction. The need for incorporating vitamin status assessment into preconception care and antenatal management algorithms for women at risk is substantiated. The findings of this review emphasize the role of nutritional support as an essential component in the prevention of obstetric and perinatal conditions.
- 10 December 2025
- Published by ECO-Vector LLC (Publications) in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 12 (4) , 381-394
Correction of vitamin status in pregnant women: current approaches and clinical significance
This systematic review aims to summarize current evidence on vitamin deficiencies in pregnant women, their clinical consequences, and approaches to nutritional status correction during gestation. Given the increasing prevalence of hypovitaminosis among pregnant women, particularly deficiencies of folic acid, vitamin D, and vitamin B12, the clinical importance of early diagnosis and individualized therapy is growing. The article analyzes studies published over the past 5 years by Russian and international authors, including randomized controlled trials, meta-analyses, cohort studies, and international clinical guidelines. Key micronutrients, their effects on the course of pregnancy, maternal and fetal outcomes, and factors contributing to impaired vitamin metabolism, including genetic polymorphisms (MTHFR, VDR, TCN2), were evaluated. The review presents approaches to laboratory diagnosis of vitamin deficiencies, principles of rational dietary therapy, and the use of vitamin–mineral supplements, as well as the potential of personalized nutritional correction. The need for incorporating vitamin status assessment into preconception care and antenatal management algorithms for women at risk is substantiated. The findings of this review emphasize the role of nutritional support as an essential component in the prevention of obstetric and perinatal conditions.
- Open Access
- 17 August 2025
- Published by ECO-Vector LLC in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 12 (3) , 285-294
Transmembrane receptor ROR1 as a therapeutic target in endometrial cancer
Endometrial cancer remains one of the most prevalent malignant neoplasms of the female reproductive system. Despite advancements in diagnostics and treatment, aggressive subtypes of the disease are characterized by high rates of metastasis, recurrence, and decreased overall survival, underscoring the need for novel therapeutic targets. One such promising molecular factor is the receptor tyrosine kinase-like orphan receptor 1 (ROR1), which is normally expressed predominantly in embryonic tissues but reactivates in various malignancies, including endometrial cancer. ROR1 plays a role in the activation of key signaling pathways such as PI3K/Akt/mTOR, MAPK, and Wnt/β-catenin, regulating processes like cell proliferation, apoptosis, invasion, and epithelial-mesenchymal transition. High ROR1 expression correlates with unfavorable clinicopathological features, including high tumor grade, advanced FIGO stages, and decreased overall survival. Moreover, ROR1 contributes to chemoresistance by activating anti-apoptotic Bcl-2 family proteins and supporting inflammatory microenvironment signaling. This article provides a comprehensive review of the molecular mechanisms involving ROR1, its role in oncogenesis and endometrial cancer progression, and its potential as both a prognostic biomarker and therapeutic target. Current approaches to targeted therapy are discussed, including the application of antibody–drug conjugates such as zilovertamab vedotin, and their prospects for clinical implementation. Given the significance of ROR1 in endometrial cancer pathogenesis, its inhibition may serve as the basis for personalized treatment strategies aimed at overcoming resistance and improving prognosis in patients with aggressive forms of endometrial cancer.
- 17 August 2025
- Published by ECO-Vector LLC in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 12 (3) , 285-294
Open AccessTransmembrane receptor ROR1 as a therapeutic target in endometrial cancer
Endometrial cancer remains one of the most prevalent malignant neoplasms of the female reproductive system. Despite advancements in diagnostics and treatment, aggressive subtypes of the disease are characterized by high rates of metastasis, recurrence, and decreased overall survival, underscoring the need for novel therapeutic targets. One such promising molecular factor is the receptor tyrosine kinase-like orphan receptor 1 (ROR1), which is normally expressed predominantly in embryonic tissues but reactivates in various malignancies, including endometrial cancer. ROR1 plays a role in the activation of key signaling pathways such as PI3K/Akt/mTOR, MAPK, and Wnt/β-catenin, regulating processes like cell proliferation, apoptosis, invasion, and epithelial-mesenchymal transition. High ROR1 expression correlates with unfavorable clinicopathological features, including high tumor grade, advanced FIGO stages, and decreased overall survival. Moreover, ROR1 contributes to chemoresistance by activating anti-apoptotic Bcl-2 family proteins and supporting inflammatory microenvironment signaling. This article provides a comprehensive review of the molecular mechanisms involving ROR1, its role in oncogenesis and endometrial cancer progression, and its potential as both a prognostic biomarker and therapeutic target. Current approaches to targeted therapy are discussed, including the application of antibody–drug conjugates such as zilovertamab vedotin, and their prospects for clinical implementation. Given the significance of ROR1 in endometrial cancer pathogenesis, its inhibition may serve as the basis for personalized treatment strategies aimed at overcoming resistance and improving prognosis in patients with aggressive forms of endometrial cancer.
- Open Access
- 11 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 6645
Causes of and Solutions to Mitochondrial Disorders: A Literature Review
Mitochondria are currently of great interest to scientists. The role of mitochondrial DNA (mtDNA) mutations has been proven in the genesis of more than 200 pathologies, which are called mitochondrial disorders. Therefore, the study of mitochondria and mitochondrial DNA is of great interest not only for understanding cell biology but also for the treatment and prevention of many mitochondria-related pathologies. There are two main trends of mitochondrial therapy: mitochondrial replacement therapy (MRT) and mitochondrial transplantation therapy (MTT). Also, there are two main categories of MRT based on the source of mitochondria. The heterologous approach includes the following methods: pronuclear transfer technique (PNT), maternal spindle transfer (MST), Polar body genome transfer (PBT) and germinal vesicle transfer (GVT). An alternative approach is the autologous method. One promising autologous technique was the autologous germline mitochondrial energy transfer (AUGMENT), which involved isolating oogonial precursor cells from the patient, extracting their mitochondria, and then injecting them during ICSI. Transmission of defective mtDNA to the next generation can also be prevented by using these approaches. The development of a healthy child, free from genetic disorders, and the prevention of the occurrence of lethal mitochondrial disorders are the main tasks of this method. However, a number of moral, social, and cultural objections have restricted its exploration, since humanity first encountered the appearance of a three-parent baby. Therefore, this review summarizes the causes of mitochondrial diseases, the various methods involved in MRT and the results of their application. In addition, a new technology, mitochondrial transplantation therapy (MTT), is currently being actively studied. MTT is an innovative approach that involves the introduction of healthy mitochondria into damaged tissues, leading to the replacement of defective mitochondria and the restoration of their function. This technology is being actively studied in animals, but there are also reports of its use in humans. A bibliographic review in PubMed and Web of Science databases and a search for relevant clinical trials and news articles were performed. A total of 81 publications were selected for analysis. Methods of MRT procedures were reviewed, their risks described, and the results of their use presented. Results of animal studies of the MTT procedure and attempts to apply this therapy in humans were reviewed. MRT is an effective way to minimize the risk of transmission of mtDNA-related diseases, but it does not eliminate it completely. There is a need for global legal regulation of MRT. MTT is a new and promising method of treating damaged tissues by injecting the body’s own mitochondria. The considered methods are extremely good in theory, but their clinical application in humans and the success of such therapy remain a question for further study.
- 11 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 6645
Open AccessCauses of and Solutions to Mitochondrial Disorders: A Literature Review
Mitochondria are currently of great interest to scientists. The role of mitochondrial DNA (mtDNA) mutations has been proven in the genesis of more than 200 pathologies, which are called mitochondrial disorders. Therefore, the study of mitochondria and mitochondrial DNA is of great interest not only for understanding cell biology but also for the treatment and prevention of many mitochondria-related pathologies. There are two main trends of mitochondrial therapy: mitochondrial replacement therapy (MRT) and mitochondrial transplantation therapy (MTT). Also, there are two main categories of MRT based on the source of mitochondria. The heterologous approach includes the following methods: pronuclear transfer technique (PNT), maternal spindle transfer (MST), Polar body genome transfer (PBT) and germinal vesicle transfer (GVT). An alternative approach is the autologous method. One promising autologous technique was the autologous germline mitochondrial energy transfer (AUGMENT), which involved isolating oogonial precursor cells from the patient, extracting their mitochondria, and then injecting them during ICSI. Transmission of defective mtDNA to the next generation can also be prevented by using these approaches. The development of a healthy child, free from genetic disorders, and the prevention of the occurrence of lethal mitochondrial disorders are the main tasks of this method. However, a number of moral, social, and cultural objections have restricted its exploration, since humanity first encountered the appearance of a three-parent baby. Therefore, this review summarizes the causes of mitochondrial diseases, the various methods involved in MRT and the results of their application. In addition, a new technology, mitochondrial transplantation therapy (MTT), is currently being actively studied. MTT is an innovative approach that involves the introduction of healthy mitochondria into damaged tissues, leading to the replacement of defective mitochondria and the restoration of their function. This technology is being actively studied in animals, but there are also reports of its use in humans. A bibliographic review in PubMed and Web of Science databases and a search for relevant clinical trials and news articles were performed. A total of 81 publications were selected for analysis. Methods of MRT procedures were reviewed, their risks described, and the results of their use presented. Results of animal studies of the MTT procedure and attempts to apply this therapy in humans were reviewed. MRT is an effective way to minimize the risk of transmission of mtDNA-related diseases, but it does not eliminate it completely. There is a need for global legal regulation of MRT. MTT is a new and promising method of treating damaged tissues by injecting the body’s own mitochondria. The considered methods are extremely good in theory, but their clinical application in humans and the success of such therapy remain a question for further study.
- Open Access
- 10 June 2025
- Published by ECO-Vector LLC in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 12 (2) , 162-171
Current perspectives on premature ovarian failure
Premature ovarian failure is a complex and multifactorial condition, the main clinical sign of which is persistent or intermittent amenorrhea lasting for at least four months. This condition is diagnosed at an age of up to 40 years. The relevance of this article lies in a more detailed examination of the causes, pathogenesis, and key clinical symptoms of premature ovarian failure. Particular attention is given to early diagnosis in women of young and middle reproductive age in order to optimize management strategies in the context of reproductive goals, as well as to the current state of scientific research. The review highlights several emerging therapeutic approaches that have shown promising results, including platelet-rich plasma (PRP) therapy, exosome-based therapy, in vitro follicle activation, stem cell therapy, microRNA-based strategies, and mitochondrial-targeted therapy. These experimental treatment strategies aim to stimulate oogenesis and folliculogenesis by enhancing natural biochemical pathways (neo-oofolliculogenesis) and improving the ovarian microenvironment.
- 10 June 2025
- Published by ECO-Vector LLC in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 12 (2) , 162-171
Open AccessCurrent perspectives on premature ovarian failure
Premature ovarian failure is a complex and multifactorial condition, the main clinical sign of which is persistent or intermittent amenorrhea lasting for at least four months. This condition is diagnosed at an age of up to 40 years. The relevance of this article lies in a more detailed examination of the causes, pathogenesis, and key clinical symptoms of premature ovarian failure. Particular attention is given to early diagnosis in women of young and middle reproductive age in order to optimize management strategies in the context of reproductive goals, as well as to the current state of scientific research. The review highlights several emerging therapeutic approaches that have shown promising results, including platelet-rich plasma (PRP) therapy, exosome-based therapy, in vitro follicle activation, stem cell therapy, microRNA-based strategies, and mitochondrial-targeted therapy. These experimental treatment strategies aim to stimulate oogenesis and folliculogenesis by enhancing natural biochemical pathways (neo-oofolliculogenesis) and improving the ovarian microenvironment.
- 10 June 2025
- Published by ECO-Vector LLC in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 12 (2) , 140-150
Impact of bariatric surgery on reproductive health in women with obesity
The issue of obesity remains highly relevant both in Russia and worldwide, becoming increasingly acute each year. Bariatric surgery in women with obesity is associated with a number of positive effects, including improved fertility, a reduced risk of gestational diabetes and pre-eclampsia due to enhanced insulin sensitivity and normalization of glucose levels. However, the intrapartum and postpartum periods are associated with several challenges, including an increased risk of micronutrient deficiencies, development of dumping syndrome, anemia, and fetal growth retardation. Therefore, it is essential to develop individualized treatment plans for patients following bariatric surgery to prevent potential complications affecting both the mother and the fetus. Special attention should be paid to additional vitamin intake and individualized dietary planning, as these are important for the future child's health. Bariatric surgery is an effective treatment for obesity, but it should only be recommended when conservative approaches—such as dietary and lifestyle modifications, pharmacotherapy, and increased physical activity—fail to achieve sufficient weight loss. When choosing this method of obesity treatment, women should be informed about possible complications, postoperative metabolic peculiarities, and the necessity of their correction. It is also important to inform patients about postoperative rehabilitation and preconception care, which should last 12–18 months after surgery before planning a pregnancy. This review was based on a search in the PubMed database using the logical operator and a combination of the following keywords: pregnancy and bariatric procedures. This search yielded 111 results, 50 of which were relevant to the study topic. The types of publications included: article type, books and documents, clinical trial, meta-analysis, randomized controlled trial, review, and systematic review. An additional publication search was conducted using the eLibrary and PubMed databases, focusing on the following keywords: ожирение и репродуктивная система (obesity and reproductive system), ожирение и бесплодие (obesity and infertility), бариатрическая хирургия (bariatric surgery), осложнения бариатрической операции (bariatric surgery complications), морбидное ожирение (morbid obesity), and беременность после бариатрической операции (pregnancy after bariatric surgery). The review includes articles published over the past 10 years.
- 10 June 2025
- Published by ECO-Vector LLC in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 12 (2) , 140-150
Impact of bariatric surgery on reproductive health in women with obesity
The issue of obesity remains highly relevant both in Russia and worldwide, becoming increasingly acute each year. Bariatric surgery in women with obesity is associated with a number of positive effects, including improved fertility, a reduced risk of gestational diabetes and pre-eclampsia due to enhanced insulin sensitivity and normalization of glucose levels. However, the intrapartum and postpartum periods are associated with several challenges, including an increased risk of micronutrient deficiencies, development of dumping syndrome, anemia, and fetal growth retardation. Therefore, it is essential to develop individualized treatment plans for patients following bariatric surgery to prevent potential complications affecting both the mother and the fetus. Special attention should be paid to additional vitamin intake and individualized dietary planning, as these are important for the future child's health. Bariatric surgery is an effective treatment for obesity, but it should only be recommended when conservative approaches—such as dietary and lifestyle modifications, pharmacotherapy, and increased physical activity—fail to achieve sufficient weight loss. When choosing this method of obesity treatment, women should be informed about possible complications, postoperative metabolic peculiarities, and the necessity of their correction. It is also important to inform patients about postoperative rehabilitation and preconception care, which should last 12–18 months after surgery before planning a pregnancy. This review was based on a search in the PubMed database using the logical operator and a combination of the following keywords: pregnancy and bariatric procedures. This search yielded 111 results, 50 of which were relevant to the study topic. The types of publications included: article type, books and documents, clinical trial, meta-analysis, randomized controlled trial, review, and systematic review. An additional publication search was conducted using the eLibrary and PubMed databases, focusing on the following keywords: ожирение и репродуктивная система (obesity and reproductive system), ожирение и бесплодие (obesity and infertility), бариатрическая хирургия (bariatric surgery), осложнения бариатрической операции (bariatric surgery complications), морбидное ожирение (morbid obesity), and беременность после бариатрической операции (pregnancy after bariatric surgery). The review includes articles published over the past 10 years.